Lipid management in chronic kidney disease, hemodialysis, and transplantation.
Recent studies have shown the spectrum of dyslipidemia in patients who have chronic kidney disease (CKD) or end-stage renal disease to be different from that of the general population. This article discusses the pathophysiology of dyslipidemia in CKD, dialysis, and renal transplant patients, the therapeutic options, and their association with clinical outcomes. Whenever possible, comparisons are made to outcomes in the general population.
Montague
Terri
T
Division of Kidney Disease and Hypertension, 593 Eddy Street, APC 9, Brown Medical School, Providence, RI 02903, USA. tmontague@lifespan.org
Murphy
Barbara
B
D002318:Cardiovascular Diseases / Q000401:mortality; D002908:Chronic Disease; D050171:Dyslipidemias / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D017408:Guidelines as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000150:complications* / Q000453:epidemiology / Q000601:surgery / Q000628:therapy; D016030:Kidney Transplantation / Q000502:physiology*; D006435:Renal Dialysis
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents